Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00972075
Recruitment Status : Completed
First Posted : September 4, 2009
Last Update Posted : September 9, 2009
Information provided by:
Neurim Pharmaceuticals Ltd.

September 3, 2009
September 4, 2009
September 9, 2009
February 2006
August 2007   (Final data collection date for primary outcome measure)
Total sleep time [ Time Frame: six weeks ]
Total sleep time
Complete list of historical versions of study NCT00972075 on Archive Site
Daily diary records of sleep latency, sleep maintenance , total duration of naps; [ Time Frame: six weeks ]
Daily diary records of sleep latency, sleep maintenance , total duration of naps;
Not Provided
Not Provided
Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects
A Double-Blind, Placebo-Controlled Study of Circadin™ for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects
The aim of this placebo-controlled randomized study was to evaluate the efficacy of Circadin™ 2 mg in improving total night sleep duration and stabilizing the circadian clock phase in totally blind subjects with non-24 hour sleep-wake disorder.
This was a multi-center, double-blind, placebo-controlled study of a once-daily (QD) dose of Circadin™ 2 mg in subjects with non-24 hour sleep-wake disorder. Subjects were initially treated with placebo for 2 weeks and then were randomly assigned in a 1:1 ratio to receive Circadin™ 2 mg or placebo for 6 weeks, followed by a 2-week washout period. The primary objective was to assess the effect of Circadin 2 mg given once daily for 6 weeks on total night sleep duration. Secondary objectives were other sleep variables recorded by the diary like sleep latency, daytime naps and sleep offset time. Other endpoints were CGIC score for Severity of Illness and Global Improvement and WHO (Five) Well-Being Index score.
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
  • Non-24 Hour Sleep-Wake Disorder
  • Blindness
  • Drug: melatonin (Circadin)
    2 mg prolonged release melatonin tablets once daily 2 hours before going to bed
    Other Names:
    • Circadin
    • ATC code N05CH01
  • Drug: placebo
    one tablet per day 2 hours before going to bed
  • Experimental: Circadin
    Circadin is 2 mg of prolonged release melatonin
    Intervention: Drug: melatonin (Circadin)
  • Placebo Comparator: Placebo
    Intervention: Drug: placebo
Roth T, Nir T, Zisapel N. Prolonged release melatonin for improving sleep in totally blind subjects: a pilot placebo-controlled multicenter trial. Nat Sci Sleep. 2015 Jan 29;7:13-23. doi: 10.2147/NSS.S71838. eCollection 2015.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
October 2007
August 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female subjects aged 20-80, having no conscious perception of light.
  • Meeting the criteria for diagnosing Non-24h cycle in the clinical setting: 1) difficulty initiating sleep or difficulty in awakening, 2) progressive delay of sleep phase with inability to maintain entrainment to 24-hour-day, and 3) presence of the sleep pattern for at least six weeks.
  • Average total night sleep duration of less than 6 hours per night for at least six weeks.
  • Ability to ingest oral medication and participate in all scheduled evaluations.
  • Signing of the Informed Consent approved by the Ethics Committee. The Informed Consent will be written in both Braille and black-and-white forms for blind subject and sighted witness.
  • Education or a work history sufficient to exclude mental retardation.
  • Stable medications for non-excluded concurrent medical conditions for four weeks prior to the screening visit.

Exclusion Criteria:

  • Presence of medical disorders other than those related to blindness and medical treatment that may influence melatonin production, sleep or alertness. To be ascertained by medical history, complete physical examination including ECG and general biochemical work-up including complete blood count, serum chemistries, and urine analysis.
  • Presence of a psychiatric or mental disorder to be assessed by a structured psychiatric interview performed by a trained individual.
  • History of seizure disorders.
  • Irregular lifestyle or life pattern (e.g. shift workers and patients unable to keep the study routine).
  • Presence of a sleep problem revealed that may explain the subjects' complaints, such as sleep disordered breathing, restless leg syndrome or periodic limb movement syndrome.
  • Use of benzodiazepines or other hypnotics during the study and preceding two weeks or 5 half lives whichever is longer.
  • Known or suspected hypersensitivity to exogenous melatonin or melatonin receptor agonists
  • Use of melatonin during preceding two weeks
  • Use of psychiatric medications during the study and preceding three months.
  • History of autoimmune diseases
  • Pharmacological immuno-suppression.
  • Pregnancy or lactation, child-bearing potential with a lack of adequate contraception.
  • History of severe pathology likely to recur during or immediately after the study.
  • Participation in a clinical trial with any investigational agent within two months prior to study enrollment.
  • Patients incapable of performing the daily call to the study IVRS system and reporting on the questionnaires.
Sexes Eligible for Study: All
20 Years to 80 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Tali Nir, VP clinical and regulatory affairs, Neurim Pharmaceuticals Ltd.
Neurim Pharmaceuticals Ltd.
Not Provided
Principal Investigator: Alan Lankford, PhD Sleep Disorders Center of Atlanta
Principal Investigator: Gary Zammit, PhD Clinlabs, Inc.
Neurim Pharmaceuticals Ltd.
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP